Animal models of fibrotic lung disease.
Bethany B. Moore,William Lawson,William Lawson,Tim D. Oury,Thomas H. Sisson,Krishnan Raghavendran,Cory M. Hogaboam +6 more
Reads0
Chats0
TLDR
Each of the models reviewed in this report offers a powerful tool for studying some aspect of fibrotic lung disease and has a much better understanding of the fact that the aged lung has increased susceptibility to fibrosis.Abstract:
Interstitial lung fibrosis can develop as a consequence of occupational or medical exposure, as a result of genetic defects, and after trauma or acute lung injury leading to fibroproliferative acute respiratory distress syndrome, or it can develop in an idiopathic manner. The pathogenesis of each form of lung fibrosis remains poorly understood. They each result in a progressive loss of lung function with increasing dyspnea, and most forms ultimately result in mortality. To better understand the pathogenesis of lung fibrotic disorders, multiple animal models have been developed. This review summarizes the common and emerging models of lung fibrosis to highlight their usefulness in understanding the cell–cell and soluble mediator interactions that drive fibrotic responses. Recent advances have allowed for the development of models to study targeted injuries of Type II alveolar epithelial cells, fibroblastic autonomous effects, and targeted genetic defects. Repetitive dosing in some models has more closely mimicked the pathology of human fibrotic lung disease. We also have a much better understanding of the fact that the aged lung has increased susceptibility to fibrosis. Each of the models reviewed in this report offers a powerful tool for studying some aspect of fibrotic lung disease.read more
Citations
More filters
Journal ArticleDOI
Single-cell RNA sequencing reveals profibrotic roles of distinct epithelial and mesenchymal lineages in pulmonary fibrosis
Arun C. Habermann,Austin J. Gutierrez,Linh T. Bui,Stephanie L. Yahn,Nichelle I. Winters,Carla L. Calvi,Lance M. Peter,Mei-I Chung,Chase J. Taylor,Christopher S. Jetter,Latha Raju,Jamie Roberson,Guixiao Ding,Lori Wood,Jennifer M.S. Sucre,Bradley W. Richmond,Bradley W. Richmond,Ana P. Serezani,Wyatt J. McDonnell,Simon B. Mallal,Simon B. Mallal,Matthew J. Bacchetta,James E. Loyd,Ciara M. Shaver,Lorraine B. Ware,Ross M. Bremner,Rajat Walia,Timothy S. Blackwell,Timothy S. Blackwell,Timothy S. Blackwell,Nicholas E. Banovich,Jonathan A. Kropski,Jonathan A. Kropski,Jonathan A. Kropski +33 more
TL;DR: It is reported that a remarkable shift in epithelial cell phenotypes occurs in the peripheral lung in PF and several previously unrecognized epithelialcell phenotypes are identified, including a KRT5−/KRT17+ pathologic, ECM-producing epithel cell population that was highly enriched in PF lungs.
Journal ArticleDOI
The instructive extracellular matrix of the lung: basic composition and alterations in chronic lung disease.
Gerald Burgstaller,Bettina Oehrle,Michael Gerckens,Eric S. White,Herbert B. Schiller,Oliver Eickelberg +5 more
TL;DR: This review summarises the available data about the structure and function of the pulmonary ECM, and highlights changes that occur in idiopathic pulmonary fibrosis (IPF), pulmonary arterial hypertension (PAH), chronic obstructive pulmonary disease (COPD), asthma and lung cancer.
Journal ArticleDOI
Evasion of apoptosis by myofibroblasts: a hallmark of fibrotic diseases.
Boris Hinz,David Lagares +1 more
TL;DR: Targeting myofibroblast apoptosis and reprogramming these cells to become scar-resolving cells are emerging as novel therapeutic strategies to reverse established fibrosis.
Journal ArticleDOI
An Official American Thoracic Society Workshop Report: Use of Animal Models for the Preclinical Assessment of Potential Therapies for Pulmonary Fibrosis.
R. Gisli Jenkins,Bethany B. Moore,Rachel C. Chambers,Oliver Eickelberg,Melanie Königshoff,Martin Kolb,Geoffrey J. Laurent,Carmel B. Nanthakumar,Mitchell Alan Olman,Annie Pardo,Moises Selman,Dean Sheppard,Patricia J. Sime,Andrew M. Tager,Amanda L. Tatler,Victor J. Thannickal,Eric S. White +16 more
TL;DR: The consensus view is that use of the murine intratracheal bleomycin model in animals of both genders, using hydroxyproline measurements for collagen accumulation along with histologic assessments, is the best‐characterized animal model available for preclinical testing.
Journal ArticleDOI
Resolution of organ fibrosis
Joon Il Jun,Lester F. Lau +1 more
TL;DR: The present knowledge and gaps in the understanding of how matrix degradation is regulated and how myofibroblast cell fates can be manipulated are discussed, areas that may identify potential therapeutic approaches for fibrosis.
References
More filters
Journal ArticleDOI
PAI-1 promotes the accumulation of exudate macrophages and worsens pulmonary fibrosis following type II alveolar epithelial cell injury
John J. Osterholzer,Paul J. Christensen,Paul J. Christensen,Vibha N. Lama,Jeffrey C. Horowitz,Noboru Hattori,Natalya Subbotina,Andrew K. Cunningham,Yujing Lin,Benjamin J. Murdock,Benjamin J. Murdock,Roger E. Morey,Michal A. Olszewski,Michal A. Olszewski,Daniel A. Lawrence,Richard Simon,Thomas H. Sisson +16 more
TL;DR: An alternative model of lung scarring is employed, in which type II alveolar epithelial cells are specifically injured by administering diphtheria toxin to mice genetically engineered to express the human DT receptor (DTR) off the surfactant protein C promoter, and it is found that this targeted AEC injury results in the diffuse accumulation of interstitial collagen.
Journal ArticleDOI
Toll-like Receptor 2 Participates In The Response To Lung Injury In A Murine Model Of Pulmonary Contusion
J. Jason Hoth,William P Hudson,Noel A. Brownlee,Barbara K. Yoza,Elizabeth M. Hiltbold,J. Wayne Meredith,Charles E. McCall +6 more
TL;DR: It is suggested that an unidentified noninfectious ligand generated by pulmonary contusion acts via TLR2 to generate inflammatory responses, which are associated with decreased levels of circulating chemokine (CXC motif) ligand 1.
Journal Article
Silicosis in mice: effects of dose, time, and genetic strain.
TL;DR: These findings demonstrate orderly dose-time-response relationships, and a substantial variation of responses among inbred strains of mice, which should prove valuable for future experimental interventions into the mechanisms of silicosis.
Journal ArticleDOI
Acid and particulate-induced aspiration lung injury in mice: importance of MCP-1
Krishnan Raghavendran,Bruce A. Davidson,Barbara A. Mullan,Alan D. Hutson,Thomas A. Russo,Patricia A. Manderscheid,James A. Woytash,Bruce A. Holm,Robert H. Notter,Paul R. Knight +9 more
TL;DR: Results indicate that MCP-1 is important for survival in murine aspiration pneumonitis and appears to act partly to protect uninjured lung regions by promoting isolation and compartmentalization of tissue with active inflammation.
Journal ArticleDOI
Susceptibility of Hermansky-Pudlak Mice to Bleomycin-Induced Type II Cell Apoptosis and Fibrosis
TL;DR: It is concluded that the trafficking abnormalities in HPS promote alveolar apoptosis and pulmonary fibrosis in response to bleomycin challenge, and type II cell susceptibility to apoptosis may play a role in the fibrotic response.
Related Papers (5)
An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-Based Guidelines for Diagnosis and Management
Ganesh Raghu,Harold R. Collard,Jim J. Egan,Fernando J. Martinez,Juergen Behr,Kevin K. Brown,Thomas V. Colby,Jean-François Cordier,Kevin R. Flaherty,Joseph A. Lasky,David A. Lynch,Jay H. Ryu,Jeffrey J. Swigris,Athol U. Wells,Julio Ancochea,Demosthenes Bouros,Carlos Roberto Ribeiro de Carvalho,Ulrich Costabel,Masahito Ebina,David M. Hansell,Takeshi Johkoh,Dong Soon Kim,Talmadge E. King,Yasuhiro Kondoh,Jeffrey L. Myers,Nestor L. Müller,Andrew G. Nicholson,Luca Richeldi,Moisés Selman,Rosalind F. Dudden,Barbara S. Griss,Shandra Protzko,Holger J. Schünemann +32 more
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis
Talmadge E. King,Williamson Z. Bradford,Socorro Castro-Bernardini,Elizabeth A. Fagan,Ian Glaspole,Marilyn K. Glassberg,Eduard Gorina,Peter Hopkins,David Kardatzke,Lisa Lancaster,David J. Lederer,Steven D. Nathan,Carlos Alberto de Castro Pereira,Steven A. Sahn,Robert Sussman,Jeffrey J. Swigris,Paul W. Noble +16 more
Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis
Luca Richeldi,Roland M. du Bois,Ganesh Raghu,Arata Azuma,Kevin K. Brown,Ulrich Costabel,Vincent Cottin,Kevin R. Flaherty,David M. Hansell,Yoshikazu Inoue,Dong Soon Kim,Martin Kolb,Andrew G. Nicholson,Paul W. Noble,Moisés Selman,Hiroyuki Taniguchi,Michèle Brun,Florence Le Maulf,Mannaig Girard,Susanne Stowasser,Rozsa Schlenker-Herceg,Bernd Disse,Harold R. Collard +22 more